AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19

 AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19

AstraZeneca Advances its AZD7442 in Two P-III Clinical Studies for COVID-19

Shots:

  • The two studies of AZD7442 will enroll ~6,000 adults for the prevention of COVID-19 in and outside the US, expected to begin in next wk. with additional trials enrolling ~4,000 adults for the treatment of SARS-CoV-2 infections.
  • The first study will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12mos. in ~5,000 participants while the second trial will assess post-exposure prophylaxis and pre-emptive treatment in ~1,100 participants
  • AstraZeneca has received ~$486M from US Govt. and plans to supply ~100,000 doses and can acquire other 1M doses. AZD7442 is a combination of 2 LAABs derived from convalescent patients after SARS-CoV-2 infection

    Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Medical Dialogues

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post